fashion -WSS

fashion

author：Wikipedia 2025-10-03 00:39:13 - browse：8

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Emergent cuts jobs, executive role in business shake

focus

WSS

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

New documents shed light on MD Anderson Cancer Institute feud

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Why failed clinical trials don’t always spell doom for a new drug

Obesity drugs seen as possible treatment for liver disease MASH

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Cancer drug shortages should be causing more outrage

What to know about Virgin Galactic's 1st mission taking paying customers to space

Affirmative action in medical school literally saved lives

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Cancer drug shortages should be causing more outrage

Obesity drugs seen as possible treatment for liver disease MASH

How one medical school became remarkably diverse

Why failed clinical trials don’t always spell doom for a new drug

Drug repurposing or repositioning? The language matters

Wegovy’s successful heart trial raises vital question about weight loss

knowledge

Community Health Systems hospitals under DOJ investigation

FDA panel issues narrow recommendation for Covid vaccine booster doses

Friends ask where James Watson's attitudes about race came from

NIH trials fail to test meaningful long Covid therapies, experts say

R1 RCM gets $5.8 billion buyout offer from private equity firm

New documents shed light on MD Anderson Cancer Institute feud

entertainment

focus

entertainment

hotspot